Findings

What do systematic reviews say?

8 questions · 8 findings · 5 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 2 · 25%Moderate 3 · 37.5%High 0 · 0%

Gene therapy vs no gene therapy control

All‐cause mortality · peripheral arterial disease

Gene therapy showed no clear difference in all‐cause mortality compared with no gene therapy control (moderate certainty).

1 finding from 1 review

Gene therapy for peripheral arterial disease 2018 · Cochrane Headline outcomes only
OR 0.93 [0.66, 1.31]
12 studies · 1685 participants
Moderate

Intramuscular injection of bone marrow mononuclear cells (BMMNC) vs control

All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy

It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).

1 finding from 1 review

Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia 2022 · Cochrane Headline outcomes only
RR 1 [0.15, 6.63]
3 studies · 123 participants
Very low

Low molecular weight heparin and idraparinux vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Idraparinux vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 1.14 [0.69, 1.86]
1 study · 2904 participants
Low

Fondaparinux plus vitamin K antagonist vs usual care

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.93 [0.45, 1.91]
2 studies · 2645 participants
Moderate

EDTA vs placebo

All‐cause mortality · atherosclerotic cardiovascular disease

EDTA showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Chelation therapy for atherosclerotic cardiovascular disease 2020 · Cochrane Headline outcomes only
RR 0.97 [0.73, 1.28]
2 studies · 1792 participants
Low

Extended prophylaxis vs another VTE extended prophylaxis

All‐cause mortalitye · patients with unprovoked venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Extended prophylaxis vs placebo

All‐cause mortalityg · patients with unprovoked venous thromboembolism

Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).

1 finding from 1 review

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with… 2017 · Cochrane Headline outcomes only
OR 1 [0.63, 1.57]
5 studies · 2043 participants
Moderate